Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy

Trial Profile

A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AG 10 (Primary)
  • Indications Amyloidosis; Cardiomyopathies
  • Focus Adverse reactions; Proof of concept
  • Sponsors Eidos Therapeutics
  • Most Recent Events

    • 18 Mar 2019 Results published in the Media Release
    • 18 Mar 2019 According to an Eidos Therapeutics media release, subgroup analyses data from this trial presented at American College of Cardiology (ACC) Scientific Sessions 2019.
    • 18 Mar 2019 According to an Eidos Therapeutics media release, data from this trial published in the Journal of the American College of Cardiology (JACC) 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top